RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 STABILITY: Darapladib and Lp-PLA2 Levels in Treatment of Atherosclerosis
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 28
OP 29
DO 10.1177/155989771427019
UL http://mdc.sagepub.com/content/14/27/28.abstract
AB The Stability of Atherosclerotic Plaque by Initiation of Darapladib Therapy trial [STABILITY; NCT00799903] showed that darapladib compared with placebo, did not significantly reduce the composite primary end point of cardiovascular death, myocardial infarction, and stroke in 15?828 patients with stable coronary heart disease on optimal medical therapy [White HD et al. N Engl J Med. 2014]. This article presents data from a predefined analysis of STABILITY designed to examine factors that contribute to high levels of Lp-PLA2 activity, whether its activity predicted outcomes or identified patients who would have a greater benefit with darapladib, and whether darapladib would provide persistent, long-term reduction of Lp-PLA2 activity.